Taiwanese Biotech Delegation Will Attend BioJapan 2026
Seventeen organizations will showcase CDMO, cell therapy, and biologics capabilities in Yokohama starting October 7.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe international biotech partnerships help expand your nation's innovation capabilities?
Seventeen Taiwanese biotech entities will participate in the BioJapan 2026 conference held from October 7 to 9, 2026. The delegation, led by the Biotechnology and Pharmaceutical Industries Promotion Office, aims to promote regional capabilities in biologics and cell therapy.
Why it matters
The delegation seeks to leverage the industry's recent growth to deepen international partnerships. Taiwan's biotech sector reached a total revenue of NT$830.1 billion in 2025, establishing a base for cross-border research and commercial collaborations.
Taiwan's biotech sector, comprising 155 public companies, achieved a total market valuation of NT$1.59 trillion (approximately US$49.8 billion) in 2025. This infrastructure now supports diverse clinical development efforts, ranging from late-stage cell therapy trials to biologics manufacturing.
The players
Biotechnology and Pharmaceutical Industries Promotion Office
A government-backed agency responsible for driving policy and international market development for the Taiwanese life sciences industry.
Steminent
A biotech firm specializing in stem cell therapeutics currently seeking regulatory approval for its Stemchymal platform in Japan.
UnicoCell
A regenerative medicine developer that has reached the Phase III trial stage for its ELIXCYTE-OA cell therapy.
Bora Biologics
A biologics manufacturer and service provider that facilitated the commercialization of RAPClot technology in the Japanese market.
LaunXP Biomedical
A life sciences company that recently expanded its operational footprint by opening a subsidiary in Kumamoto, Japan.
The details
The delegation will highlight diverse technical areas, including CDMO (contract development and manufacturing organization) services and MSC (mesenchymal stem cell) research. Companies like Steminent have applied for regulatory review with Japan's PMDA (Pharmaceuticals and Medical Devices Agency), while UnicoCell has moved into the final stages of patient enrollment for its OA (osteoarthritis) treatment. The collaboration models involve direct international expansion, such as LaunXP Biomedical establishing a local subsidiary in Kumamoto.
Timeline
2025: The Taiwan biotech sector generated NT$830.1 billion in revenue.
October 7-9, 2026: BioJapan 2026 conference duration.
October 8, 2026: Networking reception from 4:00 PM to 5:00 PM.
The Tech Race
BioJapan 2026 serves as a key venue for Taiwanese firms to integrate their pipeline products into the highly regulated Japanese life sciences market. This follows a broader strategy of using international partnerships to bridge the gap between local clinical results and global commercialization.
Industry stakeholders can monitor the progress of upcoming therapeutic approvals, such as Steminent's Stemchymal, following PMDA review. These developments impact the future availability of advanced cell therapies for patients in regional markets like Japan.
The takeaway
The Taiwanese biotech sector is pivoting from domestic growth to aggressive international clinical expansion and manufacturing partnerships. Watch for updates on the PMDA regulatory status of current stem cell candidates as a indicator of successful market entry into Japan.
Further reading
For more on emerging research and clinical developments, explore our Biotech section.
More information
View industry statistics and policy updates on the Biotech industry information portal.
Live Poll
Do you believe international biotech partnerships help expand your nation's innovation capabilities?
